You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • AB0461 Long-term use of adalimumab as monotherapy following attainment of low-disease activity: Subanalysis of the open-label extension of premier

Citation Tools

Article menu
Download PDFPDF
Scientific Abstracts
Abstracts accepted for publication
Rheumatoid arthritis – anti-TNF therapy
AB0461 Long-term use of adalimumab as monotherapy following attainment of low-disease activity: Subanalysis of the open-label extension of premier

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Keystone E, Breedveld F, Kupper H, et al
AB0461 Long-term use of adalimumab as monotherapy following attainment of low-disease activity: Subanalysis of the open-label extension of premier
Annals of the Rheumatic Diseases 2013;71:664.